蒲灵化瘀止痛方调控子宫腺肌病小鼠病灶血管生成的雌激素效应靶点的研究
|
摘要
目的：以雌激素效应相关因子、血管生成相关因子及其相互作用为靶点,探讨在AM小鼠疾病发生发展的不同时间段及子宫在位及异位内膜不同空间部位,疾病的主导机制,蒲灵化瘀止痛方治疗AM的作用机制,不同治疗剂量的横向对照,以及与现有中西医治疗方法的纵向比较。
方法：对8周龄ICR雌鼠施行雄鼠垂体宫腔内移植手术,术后分别饲养3月及6月,形成AM小鼠模型3月组及6月组。选择导师行气化瘀法临床验方(蒲灵化瘀止痛方)为实验药物,分为蒲灵化瘀止痛方高剂量组、中剂量组及低剂量组,同时将丹莪妇康煎膏作为中药对照组、孕三烯酮组为西药对照组、未造模同期小鼠为正常组。各组分别给药3月。运用免疫组化技术观察雌激素效应相关因子(p450、COX-2、ERa)及血管生成相关因子(VEGF、ENS、CD31、MMP-2、TIMP)在各模型组、各用药组随疾病发生发展的不同时间段及子宫在位及异位内膜不同空间部位的变化。
结果：1.P450在位内膜：在位内膜p450在形成AM模型后随病程进展逐渐升高,6月组显著高于3月组及正常组(P<0.01)。经治疗后,各组p450值均显著下降,造模6月后的模型组治疗后下降显著显著高于3月模型组治疗后。孕三烯酮组显著低于丹莪妇康煎膏组治疗组(P<0.05),中药的剂量对p450的影响无显著统计学差异。异位内膜：模型组异位内膜p450值显著高于正常组(P<0.01)。治疗后均显著下降,各组间比较无显著统计学差异。在疾病不同时间段(3月、6月),异位内膜P450始终显著高于在位内膜(P<0.01)。
2.ERa在位内膜：形成AM模型后3月,在位内膜ERa稍低于正常组,形成模型后6月,ERa显著高于3月模型组(P<0.05)。3月模型组治疗前后ERa值无明显变化,6月模型组治疗后有显著下降(P<0.01)。与6月模型组比较,除蒲方中低剂量治疗组外,各治疗组均显著下降(P<0.05)异位内膜：形成AM模型后6月,异位内膜ERa显著高于正常组(P<0.01)。3月模型组治疗前后ERa值无明显变化。与6月模型组比较,各组治疗后下降显著(P<0.01),高剂量组下降显著优于中、低剂量组。
3.COX-2在位内膜：形成AM模型后随病程进展逐渐升高,6月组高于3月组及正常组(P<0.01)。3月模型组治疗前后COX-2值无明显变化,与6月模型组比较,各组治疗后均显著下降,中药的高剂量组对COX-2的影响显著优于中、低剂量组(P<0.01)、(P=0.054)。异位内膜：异位内膜COX-2值6月组显著高于3月组(P<0.01)。异位内膜3月模型组治疗前后COX-2值无明显变化,与6月模型组比较,各组治疗后均显著下降,中药的高剂量组对COX-2的影响显著优于中、低剂量组(P<0.01)、(P=0.054)。
4.CD31在位内膜：形成模型后,各时间段在位内膜CD31与正常组比较均显著下降(P<0.05),CD313月模型组治疗后显著升高(P<0.01),6月模型组与3月模型组比较无显著差异；高剂量组显著高于其他各治疗组。异位内膜：各组治疗后均显著下降(P<0.01),各组间无统计学差异。而异位内膜CD31均显著高于同期在位内膜。
5.VEGF在位内膜：与正常组比较,在位内膜VEGF在形成模型后显著上调,因子的显著变化均发生于形成模型后3月组,6月组与3月组比较,无显著差异。VEGF在各治疗组后均呈显著下降趋势(P<0.01),各组间无明显差异。异位内膜：异位内膜显著下调(P<0.01)。因子的显著变化均发生于形成模型后3月组,6月组与3月组比较,无显著差异。3月组模型治疗后优于6月组治疗后。高剂量组显著优于低剂量组(P<0.05)。
6.MMP-2及TIMP在位内膜：与正常组比较,形成AM模型后在位内膜MMP-2均显著升高(P<0.05)。在位内膜MMP-2、MMP-2/TIMP,3月模型组治疗前后显著下降(P<0.05),显著优于6月模型组治疗后。与6月模型组比较,治疗后各组均显著下降,组间比较无显著差异。异位内膜：形成AM模型后6月,异位内膜MMP-2显著高于3月组异位内膜值(P<0.05)。与6月模型组比较各治疗组均显著下降(P<0.01),各组间无显著差异；MMP-2/TIMP蒲方高剂量组组及孕三烯酮组均显著下降(P<0.01),高剂量组显著优于低剂量组(P<0.05)。形成模型后,在位内膜MMP-2值上调显著高于同期异位内膜(P<0.01)。模型后3月MMP-2/TIMP比值在位内膜显著高于异位内膜(P<0.01)。
结论：1.本实验研究认为,雌激素效应因子异常、血管生成相关因子异常及其相互作用,促成了AM的发生和发展,但在疾病的不同阶段,其主导机制有所不同。疾病早期，血管生成相关因子为疾病的主导方面：在位内膜发生的微血管密度下降,局部发生缺血缺氧,从而诱发快速反应因子COX-2的急剧增高,触发COX-—PGE2—P450ar om正反馈环路,导致p450在位内膜及异位内膜随着病程进展逐渐升高。P450的增高,使局部雌激素水平增高,早期因主要通过膜受体机制,在位内膜核受体ERa并未增高。疾病中晚期，雌激素效应相关因子成为疾病的主导方面：雌激素可通过雌激素受体调节机体的多种信号途径,上调VEGF,导致异常血管增生。在位内膜及异位ERa均显著增高,雌激素主要通过核受体机制产生效应。
2.蒲灵化瘀止痛方可多靶点治疗AM,其治疗靶点可因疾病的发展阶段而不同。病程早期的中药治疗主要以血管生成相关因子为靶点,改善早期在位内膜的缺血缺氧状况,直接截断由此触发的雌激素生成的正反馈链。疾病的后阶段,血管相关因子已不再是疾病的主要环节,雌激素效应的变化主导了疾病的发展,此时,中药治疗靶点主要是在位及异位内膜雌激素效应相关因子,通过雌激素效应的变化影响血管生成因子的变化。
3.蒲灵化瘀止痛方剂量对在位内膜的CD31、VEGF、COX-2、MMP-2、MMP-2/TIMMP的影响正相关,而对雌激素效应其他因子,如P450、ERa,无显著相关性。因此,可在疾病早期运用大剂量行气活血类中药,有效改善在位内膜微循环,阻断疾病的早期触发机制；在疾病的中晚期,可以持续中低剂量使用行气活血类药物,改善雌激素效应异常,在保证治疗疗效的同时减少用药剂量,从而减少药物毒副作用,降低费用,提高患者的依从性。
4.孕三烯酮不仅有效降低了异位内膜局部雌激素及ERa水平,同时也显著降低了在位内膜的雌激素及ERa水平。与西药治疗相比,中药治疗可以避免在位内膜雌激素水平的下调。
Objective:take Estrogen effect correlator and angiogenesis correlator as target point, investigate the mean mechanism of the disease in different time and in different space of the uterus endomembrane; approach the mechanism of Chinese medicinal prescription of promoting qi to activate blood; compare the distinction between different therapeutic(al) does of Chinese medicinal formulae、and between the chinese medical science and Western medicine
Methods:carry out an operation to transplant the Male mice pituitary gland into the uterine cavity of the female mice in order to construct the AM mice model. breed the mice for3and6months to form the the model of3months and which of6months. select clinical effective medical prescription (Chinese medicinal prescription of promoting qi to activate blood) as the experimental medicine, divide into high dose group、medium dose group and low-dose group, meanwhile take soft extract of DANEFUKANG as the control group of traditional Chinese medicine, take Gestrinone as the control group of western medicine, take mice without operation as blank group, give different drugs for3months in each group. then observe the change of Estrogen effect correlator (p450、COX-2、Era) and angiogenesis correlator(VEGF、 ENS、CD31、IMMP-2、TIMMP) by immunohistochemisty technique in different time and in different space of the uterus endomembrane.
Results:
1. p450:
in the uterus endomembrane, the the value of p450gradually increase after the construction of mice model of AM, the group of3months is slightly higher the the blank group (P=0.258),the group of6months is exceed the group of3months (P=0.006); in dystopia endomembrane, the the value of p450in the group of6months notable higher than the group of3months. In the deferent period of the diease, the value of p450in dystopia endomembrane is dramatics higher than in the uterus endomembran
The value of p450is dramatics decrease after treatment in each group no matter in uterus endomembrane or in dystopia endomembrane. in uterus endomembrane, the value is significant lower in Gestrinone group than in soft extract of DAFK (P=0.038), slightly lower than which in high dose group. However in dystopia endomembrane,,there is no statistics difference between each group.
after treatmentm, the value of p450decrease in each group contrast to the model group in uterus endomembrane, which is more higher in6months group (P=0.007) than3months group. in dystopia endomembrane, the value of p450is notable decrease in each group after treatment. The drease is dramatics in6months group (P=0.001), and in3months group as well (P=0.012), the decrease is more higher in6months group than in3months group.
there is no statistics difference between different dose group wether i n uterus endomembrane or i n dystopia endomembrane
2. COX-2:
in the uterus endomembrane, the value of COX-2gradually increase after the construction of mice model of AM, the group of3months is slightly higher the the blank group (P=0.212),the group of6months is exceed the group of3months (P<0.001). in dystopia endomembrane, the the value of p450is slightly higher than in the uterus endomembrane, there is not statistically significant between the groups.
in dystopia endomembrane,, the value of COX-2is notable higher in the group of6months than in the group of3months (P=0.001) The value of COX-2is dramatics decrease after treatment in each group no matter in uterus endomembrane or in dystopia endomembrane. in dystopia endomembrane, the value is significant lower in Gestrinone group than in high dose group (P=0.052) after treatment, in uterus endomembrane, the value of COX-2has no notable change in3months group (P=0.992), however, there is a dramatics decrease in6months group.
in dystopia endomembrane, the value of COX-2has no notable change in3months group after treatment(P=0.677), however, there is a dramatics decrease in6months group.
wether in uterus endomembrane or in dystopia endomembrane, after treatment, the value of COX-2decrease dramatics in high dose group than in medium、low dose group (P=0.005)(P=0.054)。
3. ERa:
in the uterus endomembrane, the ERa in3months is slightly lower than the blank group (P=0.470), in the6months group, the value of ERa is significant exceed the value in the group of3months (P=0.029). in dystopia endomembrane, the value in the group of6months is slightly than which in group of3months (P=0.107)。In the deferent period of the diease, the value of p450in dystopia endomembrane is dramatics higher than in the uterus endomembrane
After treatment, the value of Era is decrease wether in uterus endomembrane or in dystopia endomembrane. in uterus endomembrane, the value is slightly lower in Gestrinone group than which in high dose group (P=0.236, P=0.309), there is no statistics difference between the two groups, there is no statistics difference between each group in dystopia endomembrane.
after treatment, in uterus endomembrane, the value of ERa has no notable change in3months group, however, there is a dramatics decrease in6months group. in dystopia endomembrane, the value of ERa has a dramatics decrease in each group after treatment, which is especially dramatics in6months group.
in uterus endomembrane, after treatment, the value of ERa decrease in each group, but there is no statistics difference between different dose group. in dystopia endomembrane, there is a dramatics decrease in high dose group than in medium、low dose group after treatment。
4. CD31与VEGF
MVD CD31is significant decrease in group of3months contrast to the group of blank group (P=0.006), after6months of the operation, CD31is slightly increase, but still significant lower than blank group (P=0.011)
In the deferent period of the diease, the value of p450in dystopia endomembrane is dramatics higher than in the uterus endomembrane raise up not statistically significant significant exceed;to surpass
The value of CD31is increase after treatment in each group in dystopia endomembrane. i n dystopia endomembrane, the value is significant higher in high dose group than in Gestrinone group (P<0.001) and in soft extract of DAFK group (P<0.001). in uterus endomembrane, there is no statistics difference between each group. The value of VEGF and CD31decrease in each group after treatment in dystopia endomembrane, there is no statistics difference between he chinese medical science and Western medicine. after treatment, in uterus endomembrane, the value of VEGF dramatics decrease in each model group (P<0.001); in3months group, the value of CD31has a dramatics increase in3months group (P<0.001), however, there is no significant change in6months group (P=0.945)。. in dystopia endomembrane, the value of VEGF is significant decrease wether in3months group (P=0.018) or in6months group (P=0.102); the value of CD31has downtrend wether in3months group(P=0.238) or in6months group (P=0.087)
i n uterus endomembrane, after treatment, the value of VEGF decrease in each group, but there is no statistics difference between different dose group. the value of CD31significant increase (P<0.001) after treatment which is higher in high dose group than in medium and low dose group (P<0.001) in dystopia endomembrane, the value of VEGF has a downtrend in each dose group, which is more lower in high dose group than in low dose group. The value of CD31has a downtrend in each dose group, but there is no statistics difference between different dose group.
5. MMP-2、MMP-2/TIMP:
in the uterus endomembrane, the value MMP-2significant increase after the construction of mice model of AM, the group of3months is higher the the blank group (P=0.012),the group of6months is exceed the group of3months (P=0.698). in dystopia endomembrane, the value in the group of6months is slightly than which in group of3months (P=0.027)。 after the operation, the value of MMP-2in each group is notable increase wether in the uterus endomembrane or in the dystopia endomembrane contrast to the blank group, which is more higher in the uterus endomembrane than in the dystopia endomembrane. the value of MMP-2/TIMP is higher in the uterus endomembrane than in the dystopia endomembrane, especially in the group of3months.
Contrast to the mice model group, the value of MMP/TIMMP decrease in each group wether in uterus endomembrane or in dystopia endomembrane. Which in Gestrinone group is slightly lower than the other two group, however, there is no statistics difference between the three groups. Contrast to the mice model group, the value of MMP-2significant decrease in each group wether in uterus endomembrane or in dystopia endomembrane, the value is significant lower in Gestrinone group than in high dose group (0.001) and in soft extract of DAFK group (0.042) in dystopia endomembrane. after treatment, in uterus endomembrane, the value of MMP-2、MMP-2/TIMMP, has no notable change in6months group, however, there is a dramatics decrease in3months group. in dystopia endomembrane, there is no statistics difference after treatment in each model group.
in uterus endomembrane, after treatment, the value of MMP-2decrease in group (P=0.041), which is lower in high dose group than in medium and low dose gmnp, but there is no statistics difference between different dose group. in dystopia endomembrane, there is a dramatics decrease in each dose group (P=0.002, P=0.001, P=0.001), but there is no statistics difference between different dose group. The value of MMP-2/TIMMP decrease dramatics in high dose group than in medium、low dose group after treatment。
Conclusions:
1. It can be presumed that the abnormality of Estrogen effect correlator angiogenesis correlator and the interaction of the two correlators bring about the development the AM, in defferent phase of the disease, the main mechanism is different.
In early phase, angiogenesis correlator is the main mechanism to manage the disease. In uterus endomembrane, the descend of the MVD lead to the ischemia and anoxia in local position, and then induce the pullulation of the fast reaction factor COX-2, triggering the positive feed back loop of COX-2-PGE2-P450arom, induce the value of p450gradually increase with the progress the disease. The increase of p450lead to the raise of the value of estrogen, because of the degenerative, there is a slightly decrease of the value of ERa in uterus endomembrane.
I n advanced stage, Estrogen effect correlator is the main mechanism to manage the disease. Estrogen can up-regulation the express of VEGF by receptor regulation, induce the disorder Vascular proliferation. The sensitivity of receptor descend by the continuously stimulation of the high concentration of the estrogen, which is tolerance of the estrogen. Then the level of the receptor compensatory increase, the level of ERa increase wether in uterus endomembrane or in dystopia endomembrane.
2. Chinese medicinal prescription of promoting qi to activate blood treat AM by multitarget. The target of the treatment can change along with the different stage of the disease. In early phase, angiogenesis correlator is sthe main target. The Chinese medicine can improve the situation of the anoxemia, interrupt the positive feedback link directly. In advanced stage, the angiogenesis correlator is not the main mechanism any more, Estrogen effect correlator manages the progress of the disease. At the time, the main target of the Chinese medicine is Estrogen effect correlator, the change of Estrogen effect correlator conduct the change of angiogenesis correlator.
3. The dose of the Chinese medicine is positive correlate to the express of CD31、VEGF、COX-2、MMP-2、MMP-2/TIMMP in uterus endomembrane, which has no notable correlation to the Estrogen effect correlator,such as p450、ERa. It can be presumed that using high dose of Chinese medicinal prescription of promoting qi to activate blood in early stage of the disease impeoves the microcirculation effectively, interrupt the early trigger mechanism. In adevanced stage of the disease, continuely using low-media dose Chinese medicine change the abnormity of estrogen effect, guarantee the healing,effect,, at the same time, reduce the dose of the medicine, responently reduce the toxic and side-effect, decrease the cost of the patient.
4. Gestrinone decrease the the level of ERa in not only ectopia endomembrane, but also in uterus endomembrane. Compared to the western medicine, Chinese medicine avoids the side effect of the low estrogen symptom effectly
方法：对8周龄ICR雌鼠施行雄鼠垂体宫腔内移植手术,术后分别饲养3月及6月,形成AM小鼠模型3月组及6月组。选择导师行气化瘀法临床验方(蒲灵化瘀止痛方)为实验药物,分为蒲灵化瘀止痛方高剂量组、中剂量组及低剂量组,同时将丹莪妇康煎膏作为中药对照组、孕三烯酮组为西药对照组、未造模同期小鼠为正常组。各组分别给药3月。运用免疫组化技术观察雌激素效应相关因子(p450、COX-2、ERa)及血管生成相关因子(VEGF、ENS、CD31、MMP-2、TIMP)在各模型组、各用药组随疾病发生发展的不同时间段及子宫在位及异位内膜不同空间部位的变化。
结果：1.P450在位内膜：在位内膜p450在形成AM模型后随病程进展逐渐升高,6月组显著高于3月组及正常组(P<0.01)。经治疗后,各组p450值均显著下降,造模6月后的模型组治疗后下降显著显著高于3月模型组治疗后。孕三烯酮组显著低于丹莪妇康煎膏组治疗组(P<0.05),中药的剂量对p450的影响无显著统计学差异。异位内膜：模型组异位内膜p450值显著高于正常组(P<0.01)。治疗后均显著下降,各组间比较无显著统计学差异。在疾病不同时间段(3月、6月),异位内膜P450始终显著高于在位内膜(P<0.01)。
2.ERa在位内膜：形成AM模型后3月,在位内膜ERa稍低于正常组,形成模型后6月,ERa显著高于3月模型组(P<0.05)。3月模型组治疗前后ERa值无明显变化,6月模型组治疗后有显著下降(P<0.01)。与6月模型组比较,除蒲方中低剂量治疗组外,各治疗组均显著下降(P<0.05)异位内膜：形成AM模型后6月,异位内膜ERa显著高于正常组(P<0.01)。3月模型组治疗前后ERa值无明显变化。与6月模型组比较,各组治疗后下降显著(P<0.01),高剂量组下降显著优于中、低剂量组。
3.COX-2在位内膜：形成AM模型后随病程进展逐渐升高,6月组高于3月组及正常组(P<0.01)。3月模型组治疗前后COX-2值无明显变化,与6月模型组比较,各组治疗后均显著下降,中药的高剂量组对COX-2的影响显著优于中、低剂量组(P<0.01)、(P=0.054)。异位内膜：异位内膜COX-2值6月组显著高于3月组(P<0.01)。异位内膜3月模型组治疗前后COX-2值无明显变化,与6月模型组比较,各组治疗后均显著下降,中药的高剂量组对COX-2的影响显著优于中、低剂量组(P<0.01)、(P=0.054)。
4.CD31在位内膜：形成模型后,各时间段在位内膜CD31与正常组比较均显著下降(P<0.05),CD313月模型组治疗后显著升高(P<0.01),6月模型组与3月模型组比较无显著差异；高剂量组显著高于其他各治疗组。异位内膜：各组治疗后均显著下降(P<0.01),各组间无统计学差异。而异位内膜CD31均显著高于同期在位内膜。
5.VEGF在位内膜：与正常组比较,在位内膜VEGF在形成模型后显著上调,因子的显著变化均发生于形成模型后3月组,6月组与3月组比较,无显著差异。VEGF在各治疗组后均呈显著下降趋势(P<0.01),各组间无明显差异。异位内膜：异位内膜显著下调(P<0.01)。因子的显著变化均发生于形成模型后3月组,6月组与3月组比较,无显著差异。3月组模型治疗后优于6月组治疗后。高剂量组显著优于低剂量组(P<0.05)。
6.MMP-2及TIMP在位内膜：与正常组比较,形成AM模型后在位内膜MMP-2均显著升高(P<0.05)。在位内膜MMP-2、MMP-2/TIMP,3月模型组治疗前后显著下降(P<0.05),显著优于6月模型组治疗后。与6月模型组比较,治疗后各组均显著下降,组间比较无显著差异。异位内膜：形成AM模型后6月,异位内膜MMP-2显著高于3月组异位内膜值(P<0.05)。与6月模型组比较各治疗组均显著下降(P<0.01),各组间无显著差异；MMP-2/TIMP蒲方高剂量组组及孕三烯酮组均显著下降(P<0.01),高剂量组显著优于低剂量组(P<0.05)。形成模型后,在位内膜MMP-2值上调显著高于同期异位内膜(P<0.01)。模型后3月MMP-2/TIMP比值在位内膜显著高于异位内膜(P<0.01)。
结论：1.本实验研究认为,雌激素效应因子异常、血管生成相关因子异常及其相互作用,促成了AM的发生和发展,但在疾病的不同阶段,其主导机制有所不同。疾病早期，血管生成相关因子为疾病的主导方面：在位内膜发生的微血管密度下降,局部发生缺血缺氧,从而诱发快速反应因子COX-2的急剧增高,触发COX-—PGE2—P450ar om正反馈环路,导致p450在位内膜及异位内膜随着病程进展逐渐升高。P450的增高,使局部雌激素水平增高,早期因主要通过膜受体机制,在位内膜核受体ERa并未增高。疾病中晚期，雌激素效应相关因子成为疾病的主导方面：雌激素可通过雌激素受体调节机体的多种信号途径,上调VEGF,导致异常血管增生。在位内膜及异位ERa均显著增高,雌激素主要通过核受体机制产生效应。
2.蒲灵化瘀止痛方可多靶点治疗AM,其治疗靶点可因疾病的发展阶段而不同。病程早期的中药治疗主要以血管生成相关因子为靶点,改善早期在位内膜的缺血缺氧状况,直接截断由此触发的雌激素生成的正反馈链。疾病的后阶段,血管相关因子已不再是疾病的主要环节,雌激素效应的变化主导了疾病的发展,此时,中药治疗靶点主要是在位及异位内膜雌激素效应相关因子,通过雌激素效应的变化影响血管生成因子的变化。
3.蒲灵化瘀止痛方剂量对在位内膜的CD31、VEGF、COX-2、MMP-2、MMP-2/TIMMP的影响正相关,而对雌激素效应其他因子,如P450、ERa,无显著相关性。因此,可在疾病早期运用大剂量行气活血类中药,有效改善在位内膜微循环,阻断疾病的早期触发机制；在疾病的中晚期,可以持续中低剂量使用行气活血类药物,改善雌激素效应异常,在保证治疗疗效的同时减少用药剂量,从而减少药物毒副作用,降低费用,提高患者的依从性。
4.孕三烯酮不仅有效降低了异位内膜局部雌激素及ERa水平,同时也显著降低了在位内膜的雌激素及ERa水平。与西药治疗相比,中药治疗可以避免在位内膜雌激素水平的下调。
Objective:take Estrogen effect correlator and angiogenesis correlator as target point, investigate the mean mechanism of the disease in different time and in different space of the uterus endomembrane; approach the mechanism of Chinese medicinal prescription of promoting qi to activate blood; compare the distinction between different therapeutic(al) does of Chinese medicinal formulae、and between the chinese medical science and Western medicine
Methods:carry out an operation to transplant the Male mice pituitary gland into the uterine cavity of the female mice in order to construct the AM mice model. breed the mice for3and6months to form the the model of3months and which of6months. select clinical effective medical prescription (Chinese medicinal prescription of promoting qi to activate blood) as the experimental medicine, divide into high dose group、medium dose group and low-dose group, meanwhile take soft extract of DANEFUKANG as the control group of traditional Chinese medicine, take Gestrinone as the control group of western medicine, take mice without operation as blank group, give different drugs for3months in each group. then observe the change of Estrogen effect correlator (p450、COX-2、Era) and angiogenesis correlator(VEGF、 ENS、CD31、IMMP-2、TIMMP) by immunohistochemisty technique in different time and in different space of the uterus endomembrane.
Results:
1. p450:
in the uterus endomembrane, the the value of p450gradually increase after the construction of mice model of AM, the group of3months is slightly higher the the blank group (P=0.258),the group of6months is exceed the group of3months (P=0.006); in dystopia endomembrane, the the value of p450in the group of6months notable higher than the group of3months. In the deferent period of the diease, the value of p450in dystopia endomembrane is dramatics higher than in the uterus endomembran
The value of p450is dramatics decrease after treatment in each group no matter in uterus endomembrane or in dystopia endomembrane. in uterus endomembrane, the value is significant lower in Gestrinone group than in soft extract of DAFK (P=0.038), slightly lower than which in high dose group. However in dystopia endomembrane,,there is no statistics difference between each group.
after treatmentm, the value of p450decrease in each group contrast to the model group in uterus endomembrane, which is more higher in6months group (P=0.007) than3months group. in dystopia endomembrane, the value of p450is notable decrease in each group after treatment. The drease is dramatics in6months group (P=0.001), and in3months group as well (P=0.012), the decrease is more higher in6months group than in3months group.
there is no statistics difference between different dose group wether i n uterus endomembrane or i n dystopia endomembrane
2. COX-2:
in the uterus endomembrane, the value of COX-2gradually increase after the construction of mice model of AM, the group of3months is slightly higher the the blank group (P=0.212),the group of6months is exceed the group of3months (P<0.001). in dystopia endomembrane, the the value of p450is slightly higher than in the uterus endomembrane, there is not statistically significant between the groups.
in dystopia endomembrane,, the value of COX-2is notable higher in the group of6months than in the group of3months (P=0.001) The value of COX-2is dramatics decrease after treatment in each group no matter in uterus endomembrane or in dystopia endomembrane. in dystopia endomembrane, the value is significant lower in Gestrinone group than in high dose group (P=0.052) after treatment, in uterus endomembrane, the value of COX-2has no notable change in3months group (P=0.992), however, there is a dramatics decrease in6months group.
in dystopia endomembrane, the value of COX-2has no notable change in3months group after treatment(P=0.677), however, there is a dramatics decrease in6months group.
wether in uterus endomembrane or in dystopia endomembrane, after treatment, the value of COX-2decrease dramatics in high dose group than in medium、low dose group (P=0.005)(P=0.054)。
3. ERa:
in the uterus endomembrane, the ERa in3months is slightly lower than the blank group (P=0.470), in the6months group, the value of ERa is significant exceed the value in the group of3months (P=0.029). in dystopia endomembrane, the value in the group of6months is slightly than which in group of3months (P=0.107)。In the deferent period of the diease, the value of p450in dystopia endomembrane is dramatics higher than in the uterus endomembrane
After treatment, the value of Era is decrease wether in uterus endomembrane or in dystopia endomembrane. in uterus endomembrane, the value is slightly lower in Gestrinone group than which in high dose group (P=0.236, P=0.309), there is no statistics difference between the two groups, there is no statistics difference between each group in dystopia endomembrane.
after treatment, in uterus endomembrane, the value of ERa has no notable change in3months group, however, there is a dramatics decrease in6months group. in dystopia endomembrane, the value of ERa has a dramatics decrease in each group after treatment, which is especially dramatics in6months group.
in uterus endomembrane, after treatment, the value of ERa decrease in each group, but there is no statistics difference between different dose group. in dystopia endomembrane, there is a dramatics decrease in high dose group than in medium、low dose group after treatment。
4. CD31与VEGF
MVD CD31is significant decrease in group of3months contrast to the group of blank group (P=0.006), after6months of the operation, CD31is slightly increase, but still significant lower than blank group (P=0.011)
In the deferent period of the diease, the value of p450in dystopia endomembrane is dramatics higher than in the uterus endomembrane raise up not statistically significant significant exceed;to surpass
The value of CD31is increase after treatment in each group in dystopia endomembrane. i n dystopia endomembrane, the value is significant higher in high dose group than in Gestrinone group (P<0.001) and in soft extract of DAFK group (P<0.001). in uterus endomembrane, there is no statistics difference between each group. The value of VEGF and CD31decrease in each group after treatment in dystopia endomembrane, there is no statistics difference between he chinese medical science and Western medicine. after treatment, in uterus endomembrane, the value of VEGF dramatics decrease in each model group (P<0.001); in3months group, the value of CD31has a dramatics increase in3months group (P<0.001), however, there is no significant change in6months group (P=0.945)。. in dystopia endomembrane, the value of VEGF is significant decrease wether in3months group (P=0.018) or in6months group (P=0.102); the value of CD31has downtrend wether in3months group(P=0.238) or in6months group (P=0.087)
i n uterus endomembrane, after treatment, the value of VEGF decrease in each group, but there is no statistics difference between different dose group. the value of CD31significant increase (P<0.001) after treatment which is higher in high dose group than in medium and low dose group (P<0.001) in dystopia endomembrane, the value of VEGF has a downtrend in each dose group, which is more lower in high dose group than in low dose group. The value of CD31has a downtrend in each dose group, but there is no statistics difference between different dose group.
5. MMP-2、MMP-2/TIMP:
in the uterus endomembrane, the value MMP-2significant increase after the construction of mice model of AM, the group of3months is higher the the blank group (P=0.012),the group of6months is exceed the group of3months (P=0.698). in dystopia endomembrane, the value in the group of6months is slightly than which in group of3months (P=0.027)。 after the operation, the value of MMP-2in each group is notable increase wether in the uterus endomembrane or in the dystopia endomembrane contrast to the blank group, which is more higher in the uterus endomembrane than in the dystopia endomembrane. the value of MMP-2/TIMP is higher in the uterus endomembrane than in the dystopia endomembrane, especially in the group of3months.
Contrast to the mice model group, the value of MMP/TIMMP decrease in each group wether in uterus endomembrane or in dystopia endomembrane. Which in Gestrinone group is slightly lower than the other two group, however, there is no statistics difference between the three groups. Contrast to the mice model group, the value of MMP-2significant decrease in each group wether in uterus endomembrane or in dystopia endomembrane, the value is significant lower in Gestrinone group than in high dose group (0.001) and in soft extract of DAFK group (0.042) in dystopia endomembrane. after treatment, in uterus endomembrane, the value of MMP-2、MMP-2/TIMMP, has no notable change in6months group, however, there is a dramatics decrease in3months group. in dystopia endomembrane, there is no statistics difference after treatment in each model group.
in uterus endomembrane, after treatment, the value of MMP-2decrease in group (P=0.041), which is lower in high dose group than in medium and low dose gmnp, but there is no statistics difference between different dose group. in dystopia endomembrane, there is a dramatics decrease in each dose group (P=0.002, P=0.001, P=0.001), but there is no statistics difference between different dose group. The value of MMP-2/TIMMP decrease dramatics in high dose group than in medium、low dose group after treatment。
Conclusions:
1. It can be presumed that the abnormality of Estrogen effect correlator angiogenesis correlator and the interaction of the two correlators bring about the development the AM, in defferent phase of the disease, the main mechanism is different.
In early phase, angiogenesis correlator is the main mechanism to manage the disease. In uterus endomembrane, the descend of the MVD lead to the ischemia and anoxia in local position, and then induce the pullulation of the fast reaction factor COX-2, triggering the positive feed back loop of COX-2-PGE2-P450arom, induce the value of p450gradually increase with the progress the disease. The increase of p450lead to the raise of the value of estrogen, because of the degenerative, there is a slightly decrease of the value of ERa in uterus endomembrane.
I n advanced stage, Estrogen effect correlator is the main mechanism to manage the disease. Estrogen can up-regulation the express of VEGF by receptor regulation, induce the disorder Vascular proliferation. The sensitivity of receptor descend by the continuously stimulation of the high concentration of the estrogen, which is tolerance of the estrogen. Then the level of the receptor compensatory increase, the level of ERa increase wether in uterus endomembrane or in dystopia endomembrane.
2. Chinese medicinal prescription of promoting qi to activate blood treat AM by multitarget. The target of the treatment can change along with the different stage of the disease. In early phase, angiogenesis correlator is sthe main target. The Chinese medicine can improve the situation of the anoxemia, interrupt the positive feedback link directly. In advanced stage, the angiogenesis correlator is not the main mechanism any more, Estrogen effect correlator manages the progress of the disease. At the time, the main target of the Chinese medicine is Estrogen effect correlator, the change of Estrogen effect correlator conduct the change of angiogenesis correlator.
3. The dose of the Chinese medicine is positive correlate to the express of CD31、VEGF、COX-2、MMP-2、MMP-2/TIMMP in uterus endomembrane, which has no notable correlation to the Estrogen effect correlator,such as p450、ERa. It can be presumed that using high dose of Chinese medicinal prescription of promoting qi to activate blood in early stage of the disease impeoves the microcirculation effectively, interrupt the early trigger mechanism. In adevanced stage of the disease, continuely using low-media dose Chinese medicine change the abnormity of estrogen effect, guarantee the healing,effect,, at the same time, reduce the dose of the medicine, responently reduce the toxic and side-effect, decrease the cost of the patient.
4. Gestrinone decrease the the level of ERa in not only ectopia endomembrane, but also in uterus endomembrane. Compared to the western medicine, Chinese medicine avoids the side effect of the low estrogen symptom effectly
引文
[1]魏绍斌,曹亚芳.从湿热瘀结论治子宫内膜异位症探讨[J].中国中医基础医学杂志,2006,12(10)：757—758
[2]魏绍斌,黄金燕,文怡.从湿瘀内结论治妇科慢性盆腔疼痛病症[J].四川中医,2012,30(4)：29—30
[3]魏绍斌,黄金燕,文怡.从湿瘀内结论治妇科慢性盆腔疼痛病症[J].四川中医,2012,30(4)：29—30
[4]魏绍斌,冯婷婷,王宇慧.从“源头治疗”子宫内膜异位症的中医新思路[J].新中医,2012,44(11)：14—16
[5]段峻.四物汤加味治疗子宫腺肌症51例[J].河北中医,1999,21(6)：363—364
[6]李所平.少腹逐瘀汤加味治疗子宫腺肌病50例[J].河北中医,2009,31(4)：592
[7]李学应,杨廉泽.散结汤治疗子宫肌瘤子宫腺肌症的临床研究[J].浙江中医药大学学报,2006,30(4)：365—367
[8]王清.“抑痛平”治疗子宫腺肌症痛经35例临床观察[J].中国康复理论与实践,2005,11(8)：651—652
[9]彭秀美.自拟验方治疗子宫腺肌症[J].中国医学杂志,2006,4(12)：683—684
[10]秦瑞英.散结镇痛胶囊治疗子宫腺肌症并不孕的临床观察[J].中国医药导报,2006,3(26)：95
[11]朱江艾.桂枝茯苓胶囊治疗子宫腺肌病56例[J].中华现代中西医杂志,2005,(13)：1218
[12]叶铤.子宫腺肌症的早期中药治疗.中国中医药信息杂志[J],2003,10(5)：47--48
[13]沈玉莲,金季玲.活血化淤法分期治疗子宫腺肌病27例临床观察[J].时珍国医国药,2006,17(10)：2037-2038
[14]李亚平.少腹逐瘀汤灌肠治疗子宫腺肌症32例[J].中医杂志,2003,44(1)：49
[15]侯钦銮,吕洪清,汪慧敏.药灸结合治疗子宫腺肌症的临床观察[J].浙江中医学院学报,2004,28(6)：42-43
[16]李琼,邓雪梅,赖慧红.健脾补肾祛瘀3法分期治疗子宫腺肌病20例临床观察[J].中医杂志,2004,45(7)：520—521
[17]刘秀峰,陈丽笙,何珍.大黄廑虫丸治疗子宫腺肌病30例观察[J].实用中医药杂志,2004,20(2)：64—65
[18]张秋晔,韩英俊,白晓玲.自拟谐宫汤活血化瘀药为主治疗子宫腺肌病的临床观察与优势[J].中国初级卫生保健,2008,11(22)：94—95
[19]邓雷厉.化瘀消瘸方合灌肠液治疗子宫腺肌病临床观察[J].中医药学刊,2005,23(3)：570-573
[20]田洪兰,麻增昌,刘传文.小剂量米非司酮配合中药治疗子宫腺肌病的临床观察[J].潍坊医学院学报,2005,27(6)：458-459
[21]曹丽蓉,李力.中西医结合治疗围绝经期子宫腺肌病60例[J].中国中西医结合杂志,2005,25(11)
[22]董小萍.中西医结合治疗子宫腺肌病30例[J].湖北中医杂志,2005,27(9)：34
[23]杨君,任艳芳,华芳芳.改良式手术联合散结镇痛胶囊治疗子宫腺肌症的临床研究[J].医学信息内外科版,2009年6,22(6)：501—503
[24]黄为宁,王劲琪,曹长健等.双侧子宫动脉栓塞联合中药治疗[J].时珍国医国药,2007,18(2)：475—476
[25]Wang J, Zhang HH, Duan H. Expression of ER a in endometrial—myometria interface of human adenomyosis[J]. Zhonghua Yi Xue Za Zhi.2010:90(27):1914-19177.
[26]陆晓媛.子宫腺肌病中孕激素受体亚型表达的研究[J].中国实用医药,2008,3(35)：45—46
[27]高珍珍,宋磊,关铮.选择性雌激素受体β激动剂治疗小鼠子宫腺肌病的实验研究[J].中国妇产科临床杂志2009,10(3)：210--211
[28]郭志荣,张琚,郎景和.子宫腺肌症患者在位子宫内膜雌激素效应相关因子的时空变化[J].中华妇产科杂志,2004,39(42)：246—247
[29]Jichan Nie, Xishi Liu, Guo SW. Promoter hypermethylation of progesterone receptor isoform B (PR—B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent[J]. Reprod Sci.2010,17(11):995-1005.
[30]Hatok J, Zubor P, Galo S. Endometrial aromatase mRNA as a possible screening tool for advanced endometriosis and adenomyosis[J]. Gynecol Endocrinol,2010,17:118-120
[31]黄晓晖,康佳丽,王小霞,等.Bcl-2蛋白、Ki-67抗原、雌激素受体及孕激素受体在 子宫腺肌病子宫内膜中的表达[J].中华生物医学工程杂志,2007,13(4)：198—199
[32]邓亚丽,胡春兰,李晓玲Survivin在子宫腺肌病的表达及其与Bcl-2、Bax相关性的研究[J].医学研究杂志,2008,37(6)：17-20
[33]郑立红,岳丽玲,刘枫Fas、FasL在子宫腺肌病中的表达及意义[J].中国优生与遗传杂志2005,13(12)：28—29
[34]Yang JH, Wu MY, Chen CD, Chen MJ, Yang YS, Altered apoptosis and proliferation in endometrial stromal cells of women with adenomyosis[J]. Ho HNHum Reprod.2007 Apr;22 (4):945-52.
[35]张爱群,孙富国,李金生,等cyclin E与P27蛋白在子宫腺肌病中的表达及临床意义[J].临床军医杂志,2007,35(1)：13—14
[36]张爱群,付红霞,孙富国,等Cyclin A与P2 1蛋白在子宫腺肌病中的表达及临床意义[J].河北医药,2007,29(11)：1163—1164
[37]张蓉,虞斌,许培箴,等.端粒酶在子宫腺肌病中的表达及其临床意义[J].中国临床医学,2007,14(6)：854—855
[38]刘俊宝,金海鸿,张爱臣.诱导细胞凋亡c—myc在子宫腺肌病中的表达及意义[J].中国实验诊断学,2008,12(4)：466—467
[39]Huang HY, Yu HT, Chan SH, Lee CL, Wang HS, Soong YK. Eutopic endometrial interleukin-18 system mRNA and protein expression at the level of endometrial—myometrial interface in adenomyosis patients[J]. Fertil Steril.2010 Jun;94(1):33-39.
[40]Wang F, Li H, Yang Z, Du X, Cui M, Wen Z Expression of interleukin-10 in patients with adenomyosis[J]. Fertil Steril.2009 May;91(5):1681-1685
[41]Ulukus M, Ulukus EC, Seval Y, Cinar O. Expression of interleukin-8 receptors in patients with adenomyosis [J]. Fertil Steril.2006 Mar; 85(3):714-720.
[42]Yang JH, Chen MJ, Wu MY, Chen YC, Yang YS, Ho HN.. Decreased suppression of interleukin-6 after treatment with medroxyprogesterone acetate and danazol in endometrial stromal cells of women with adenomyosis[J]. Fertil Steril.2006 Nov;86(5):1459-1465.
[43]曲晓媛,贾世磊,王言.芳香化酶P450与环氧化酶-2在子宫内膜异位症和子宫腺肌病 中的表达及意义[J].中国现代医药杂志,2009,11(5)：27--28
[44]王言奎,徐冰,车艳辞.子宫内膜异位症和子宫腺肌病P450arom和COX-2mRNA的表达及意义[J].青岛大学医学院学报,2007,43(4)：326—328
[45]王毅峰,曲银娥,杨梅.COX-2基因多态性与子宫内膜异位症及子宫腺肌病关系的研究[J].山东医药,2007,47(15)：55—57
[46]王杜平,王进京.子宫腺肌病患者在位与异位内膜热休克蛋白27的表达及意义[J].右江民族医学院学报,2007,29(3)：416—417
[47]Wang F, Wen Z, Li H, Yang Z, Zhao X, Yao X. Human leukocyte antigen—G is expressed by the eutopic and ectopic endometrium of adenomyosis[J]. Fertil Steril.2008 Nov; 90 (5):1599-1604.
[48]赵瑞,李艳,赵蔚.子宫腺肌病中异位子宫内膜血管发生的研究[J].医药论坛杂志,2007,28(21)：38-39
[49]吕晓霞,李楠.子宫腺肌病组织中PTTG、bFGF和VEGF的表达及意义[J].山东医药,2008,48(3)：97
[50]Kang S, Zhao J, Liu Q, Zhou R, Wang N, Li Y. Vascular endothelial growth factor gene polymorphisms are associated with the risk of developing adenomyosis[J]. Environ Mol Mutagen.2009 Jun; 50 (5):361-366.
[51]Liu Q, Li Y, Zhao J, etc. Association of single nucleotide polymorphisms in VEGF gene with the risk of endometriosis and adenomyosis[J]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi.2009 Apr;26(2):165-169.
[52]刘天凤,尹福波.子宫腺肌病组织中PTFG的表达与微血管密度和b-FGF的关系[J].现代妇产科进展,2007,16(4)：300
[53]马小梅,李娜萍,刘海防.中期因子在GnR H a治疗后子宫腺肌病患者在位和异位内膜组织中的表达[J].华中科技大学学报(医学版),2009,38(1)：64-65
[54]王水英,周彩云,付晓敏Ang-1和Ang-2在子宫内膜异位症及子宫腺肌病中的表达[J].中国妇产科临床杂志,2008,9(3)：77—78
[55]李梦熊,张怡,蔡净亭.促血管生成素-2在子宫内膜异位性疾病中的表达及其意义[J].中国医学工程,2007,15(1)：211-212
[56]胡亚敏,郑红兵VEGF-C和ICAM-1在子宫腺肌病中的表达及意义[J].华中科技大学 学报(医学版),2009,38(2)：218—219
[57]Zhang X, Lu B, Huang X, Xu H, Zhou C, etc. Innervation of endometrium and myometrium in women with painful adenomyosis and uterine fibroids [J]. Fertil Steril. 2010 Jul;94(2):730-737.
[58]Choi YS, Cho S, Lim KJ, Jeon YE, etc. Effects of LNG—IUS on nerve growth factor and its receptors expression in patients with adenomyosis [J]. Growth Factors.2010 Dec; 28 (6):452-460.
[59]李天真.蒲灵化瘀止痛方对子宫腺肌病模型小鼠异位和在位内膜血管生成相关因子不同影响的实验研究[D].成都中医药大学,2011.
[60]马俊彦,冯燕,许泓,等.小鼠子宫腺肌病模型的建立及ER的表达[J].中国保健营养(临床医学学刊),2009,18(4)：29—31
[61]廖英,李军兰,陈云飞.桂枝茯苓胶囊对子宫腺肌病小鼠病灶组织MMP-2、MMP-7的影响[J].中国中医药科技,2007,14(5)：328—330
[62]李雁,张绍芬,夏贤,等.口服他莫昔芬法建立ICR小鼠子宫腺肌病模型[J].中国实验动物学报,2009,17(5)：29—31
[63]张信美,邓琳,马俊彦,等.异体垂体移植诱发ICR小鼠子宫腺肌病动物模型的建立[J].现代妇产科进展,2007,16(4)：94--96
[64]李雁,张绍芬,夏贤,等.口服他莫昔芬法建立ICR小鼠子宫腺肌病模型[J].中国实验动物学报,2009,17(5)：：345—350
[65]尤昭玲,付灵梅,谭朝阳,等.三七有效成分对人子宫内膜细胞培养液TNF-α和IL—1β含量的影响[J].中国实验方剂学杂志,2005,11(2)：39—41
[66]孙蓬明,宋一一,高敏等.ERRa过度表达对子宫内膜癌Ishikawa细胞内分泌治疗的影响[J].中国妇产科临床杂志,2012,13(2)：126—127
[67]张宝玉,万杰PR、ER在食管癌组织中的表达及与预后的关系[J].山东医药,2012,52(43)：38—39
[68]李玉娟,谢静燕.雌激素受体基因多态性与子宫内膜异位症的相关性[J].安徽医药,2010,14(11)：1305—1307
[69]李靖,冯力民,刘晖.雌孕激素受体在子宫全层中的表达[J].武警医学,2011,22(12)：1049—1051
[70]华特波,孟宪瑛,张强,等.COX-2、MMP-9在甲状腺癌中的表达及临床意义[J].中国实验诊断学,2011,15(9)：1491—1493
[71]马静,何朝宏,任君凯,等COX-2、NF-κ BmR N A在肾透明细胞癌中的表达变化及意义[J].山东医药,2012,52(10)：75—77
[72]唐曼,吴强,吴正升,等.COX-2在食管鳞状细胞癌组织中的表达及相互关系[J].安徽医科大学学报；450-453
[73]邓莅霏,齐淑轶,刘学明,等COX-2、VEGF—C在头颈鳞癌中的表达及意义[J],赣南医学院学报,32(4)：515—517
[74]董毅,程艳香.COX-2和HIF—1α在宫颈鳞状细胞癌组织中的表达及意义[J].实用癌症杂志,2012,27(1)：36—37
[75]辛华,江清林,崔国利,等.COX-2和M MP—9在乳腺癌患者血清中检测的意义[J].中国病案,2012,13(2)：46—47
[76]李杰,陈剑秋,王新允,等.COX-2和MUC—1在乳腺癌中的表达及其临床意义[J].天津医科大学学报,2011,17(4)：479—481
[77]陈怡文,龚享文,刘春云.COX-2基因mRNA在非小细胞肺癌中的表达[J].临床肺科杂志2012,17(5)：935—936
[78]秦卫华,吕红凯.COX-2在肾癌中的表达及其临床意义[J].求医问药,2011,9(8)：11—13
[79]黄利娟,陈勃.COX-2在子宫内膜病变发生发展中的作用[J].广州医药,2012,43(3)：27—29
[80]孙丽,孙三元,卓士超,等HER-2、COX-2和VEGF在乳腺癌原发灶与复发转移灶之间的关系[J].临床肿瘤学杂志,2011,16(11)：984—987
[81]贾富鑫,刘江伟,张东.MMP—9和COX-2蛋白的表达对胰腺癌预后的影响[J].中华临床医师杂志(电子版),2011,5(7)：7191
[82]张帅,沈梁,谷维立,等VEGF、COX-2在甲状腺癌中的表达及临床意义[J].医学研究杂志,2012,41(2)：146—150
[83]马隽,陈晓明,钟艳平,等.骨肉瘤组织中COX-2、VEGF的表达及意义[J].山东医药,2011,51(10)：7—9
[84]奚豪,朱延波,蒋虹伟,等.食管癌COX-2和VEGF的表达及其与临床病理特征的关系[J]. 局解手术学杂志,2011,20(2)：157—159
[85]杨莉,刘廷健,鲍静娴.胃癌组织中COX-2和VEGF—CmRNA表达及意义[J].中国当代医药,2011,18(13)：10—12
[86]姚婷婷,章礼久,方海明.肠道细胞色素P450代谢酶研究进展[J].安徽医药,2012,16(6)：721—723
[87]徐永红,孙航,郭晖,等.肝再生增强因子、细胞色素P450与人肝癌细胞在体外耐药的关系[J].重庆医科大学学报,2011,6(3)：257—262
[88]高桂芹,林琬君,李宝森.芳香化酶细胞色素P450在子宫内膜异位症中的检测与临床意义[J].天津医药,38(12)：1050-1052
[89]黄秋穗,侯晓红.那曲唑对子宫内膜异位症芳香化酶P450、雌二醇及雌激素受体的影响[J].临床研究,2011,49(25)：54—56
[90]刘燕,康佳丽,王小霞VEGF、ENS、MVD在子宫腺肌病中的表达及意义[J].中国妇产科临床杂志,2009,10(5)：363—366
[91]刘春花,崔之础,张玉泉VEGF基因多态性与子宫内膜异位症的相关性研究[J].南通大学学报(医学版),2012,32(6)：513—515
[92]姚路明.基质金属蛋白酶MMP-2、MMP-9含量表达与大肠癌浸润转移相关性研究[J].吉林医学,2012,33(34)：7461—7462
[93]韩迎春,李剑,孙启玉,等.腹股沟直疝及斜疝患者皮肤组织MMP—2及T I MP—2的表达研究结论[J].现代中西医结合杂志.2012,21(22)：2403—2405
[94]李守勇,陈维霞,孙阳.类风湿性关节炎患者血清中s CR1和MMP-2、MMP-9水平的检测及其临床意义[J].中国实用医刊,2012,39(24)68—70
[95]夏正明.急性发作期支气管哮喘患者血清IL-18、MMP-9、COX-2水平的变化及意义[J].实用临床医学,2012,13(8)：22—24
[96]张弘炜,王太洪,卢有胜.MMP-2与HGF在胰腺癌组织中的表达及临床意义[J].中国肿瘤外科杂志,2012,4(6)：338—340
[97]李燕,郑芹林,唐利Int β1、MMP-2及PRL-3在子宫内膜异位症中的表达[J].山东医药,2012,52(41)：35—37
[98]胡倩,于丽,廖秦平.基质金属蛋白酶-2基因启动子的甲基化状态对子宫内膜癌侵袭力调控的分子机制[J].北京大学学报,44(6)：911—915
[99]Choi YS, Cho S, Lim KJ, etal. Immunoreactivity of progesterone receptor isoform B, nuclear factor kappaB, and I kappaB alpha in adenomyosis[J]. Fertil Steril, 2009,92(3):886-889
[100]Hudelist G, Keckstein J,Czerwenka K, et al. Estrogen receptor beta and matrix metalloproteinase are coexpressed in uterine endometrium and endometriotic lesions of patients with endometriosis[J].Fertil Steril,2005,84(2):1249-1256
[101]NieJC, Xishi LiuXS, Guo SW. Promoter hypermethylation of progesterone receptor isoform B (PR—B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent[J]. Reprod Sci.2010,17(11):995-1005.
[102]张拴成,肖红玲,王丽娜,等.消瘀通络散对乳腺增生大鼠乳头的动态变化、血清雌二醇、雌激素受体表达水平及病理组织形态的影响[J].浙江中医药大学学报,2012,36(4)：417—421
[103]骆殊,邵佳,沈洪,等.黄芪莪术配伍抑制MKN-45裸鼠人原位胃癌模型肿瘤生长、转移及COX-2表达的增效研究[J].时珍国医国药,2012,23(5)：1164—1165
[104]佘小翠,黄丽军,刘高峰,等.丹红注射液对大鼠肝微粒体5种CYP亚型酶活性的影响[J].医药导报,2012,31(3)：277—278
[105]段保宏,高完花,魏娜.四物合剂对大鼠肝微粒体代谢酶P450活性的影响[J].中国药物与临床,2011,11(5)：600—602
[106]应忠明,蔡永强,王恩智.实验性脑出血大鼠VEGF及MMP-9蛋白表达的影响及益气活血法的干预作用[J].中国高等医学教育,2012,12：131
[107]宗慧梅,王禹.活血化瘀中药对实验陛急性脑梗死大鼠脑组织VEGF、bFGFmRNA表达的影响[J].中国中医急症,2006,15(7)：766—767
[108]郭海,陈艳,尹刚,等.养肺活血方对肺纤维化大鼠肺组织血管新生的影响[J].南京中医药大学学报,2012,28(5)：467—468
[109]倪秀琴,魏仲南,林武,等.益肾通络方治疗慢性肾衰竭及与血清TGF-p、VEGF的相关研究[J].中国中西医结合肾病杂志,2012,13(12)：1099—1100
[110]孙垮,张苗,蒋春明.丹参酮ⅡA对腹膜透析患者基质金属蛋白酶及金属蛋白酶组织抑制剂-1的影响[J].医学研究生学报,2011,24(9)：913—914
[111]林薇,赵锦燕,郑良朴,等.血府逐瘀汤对大鼠血管平滑肌细胞MMP-2、TIMP-1表达 的影响[J].时珍国医国药,2011,22(11)：2667—2668
[112]姜元辉,段富津.益气养血化瘀汤对心肌缺血大鼠MMP-2和MMP-9蛋白表达的影响[J].中医药学报,2012,40(2)：47—49
[113]杨东霞,曲凡,马文光,等.活血化瘀法对子宫内膜异位症模型大鼠E2、P、VEGF的影响[J].成都中医药大学学报,2006,29(2)：28—30
[114]钟凌,袁立明.血府逐瘀汤对子宫肌瘤雌激素受体和BCL-2表达的影响[J].肿瘤药学,2012(1)：34—35
[115]唐润娟,程慧莲.消瘤丸对子宫内膜异位症大鼠异位病灶的影响[J].内蒙古中医药,2012,3：41-42
[116]杨正望,文炯,张增玲.补肾化瘀方对PCOS大鼠卵巢颗粒细胞CYP450表达的影响[J].湖南中医药大学学报,2011,31(1)：30—33
[117]杜永红,李沛霖,韩冰.补肾调冲方对去卵巢大鼠性激素水平及下丘脑雌激素受体a、雌激素受体β m RNA表达的影响[J].天津中医药,2011,28(3)：240—243
[118]姚菲,曹建雄,王若光.桂枝挥发油对PCOS大鼠模型卵巢VEGF、COX-2及MVD表达的影响[J].中医药导报,18(1)：15-17
[119]贺丰杰,李小宁,张文婷.凋膜止崩液宫腔靶向给药对ADUB模型大鼠子宫内膜组织中MMP-1、TIMP-1、ER及亚型表达的影响[J].时珍国医国药,2012,23(6)：1861—1863
[120]]丁青,李洁雅,徐杰,等.丹参注射液对中重度IUA患者宫内膜α V β 3、P DGF及TIMP-1的影响[J].湖南中医药大学学报,2012,32(10)：52—55
[121]A. Vivaequa, D. Bonofigli o, A. G. Recchia,et al.The G p rotein coupled receptor GPR30 mediates the proliferative eff ects induced by 17B-estradiol and hydroxytamoxifen in endometri M cancer cells [J].Mol Endocfinol,2006,20:631-646
[122]T. Smuc.M. Ribie—ueelj, J. inkovec, et al. Expression analy sis of the genes involved in estradiol and progesterone action in human ovarian endome-triosis [J].Gynecol Endocrinol,2007,23:105-111
[123]Bukulrn 0, Hardy D. B, Cart B. R, et al. Mendel son, Inflammato ry status influences aronmtase and steroid expression in endome triosis [J].Endocrinology,2008,149:1190-1204
[124]A. Vivaequa, D. Bonofigli o, A. G. Recchia, et al.The G p rotein coupled receptor GPR30 mediates the proliferative eff ects induced by 17B-estra-diol and hydroxytamoxifen in endometri M cancer cells [J]. Mol Endocfinol,2006,20:631-646
[125]端传友MMP-2、MMP-9及VEGF在结肠癌中的表达及其与肿瘤转移的相关性[J].中国医药导报,2012,9(21)：44—48
[1]赵瑞,李艳,赵蔚.子宫腺肌病中异位子宫内膜血管发生的研究[J].医药论坛杂志,2007,28(21)：38-39
[2]吕晓霞,李楠.子宫腺肌病组织中PTTG、bFGF和VEGF的表达及意义[J].山东医药,2008,48(3)：14-15
[3]Kang S, Zhao J, Liu Q, Zhou R, Wang N, Li Y. Vascular endothelial growth factor gene polymorphisms are associated with the risk of developing adenomyosis[J]. Environ Mol Mutagen,2009,50(5):361-366.
[4]. Liu Q, Li Y, Zhao J, etc. Association of single nucleotide polymorphisms in VEGF gene with the risk of endometriosis and adenomyosis[J]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi.2009 Apr; 26 (2):165-169.
[5]李梦熊,张怡,蔡净亭.促血管生成素-2在子宫内膜异位性疾病中的表达及其意义[J].中国医学工程,2007,15(1)：211-212
[6]陈华,马生秀.促红细胞生成素在子宫腺肌病组织的表达意义[J].青海医学院学报2009,30(1)：40
[7]Wang J, Zhang HH, Duan H. Expression of ER a in endometrial- myometria interface of human adenomyosis[J]. ZhonghuaYiXue ZaZhi.2010;90(27): 1914-19177.
[8]Ocher Klein K, Janfaza M, Wang J A, Chang R J. Estrogen bioactivity in fo-ti and other herbs used for their estrogen-like effects as determined by a recombinant cell bioassay[J]. J Clin Endocrinol Metab, 2003,88(9):4077-4079.
[9]曲晓媛,贾世磊,王言.芳香化酶P450与环氧化酶-2在子宫内膜异位症和子宫腺肌病中的表达及意义[J].中国现代医药杂志,2009,11(5)：27-28
[10]王言奎,徐冰,车艳辞.子宫内膜异位症和子宫腺肌病P450arom和COX-2mRNA的表达及意义[J].青岛大学医学院学报,2007,43(4)：326-328
[11]刘天凤,尹福波.子宫腺肌病组织中PTFG的表达与微血管密度和b-FGF的关系[J].现代妇产科进展,2007,16(4)：300
[12]刘素巧,董晓瑜,申莉瑛等.基质金属蛋白酶-2在子宫腺肌病子宫内膜-肌层界面的表达[J].河北医药,2009,31(2)：
[13]康佳丽,李莉,杜洪等.基质金属蛋白酶-7及其抑制因子-1在子宫腺肌 病中的表达及意义[J].中华妇幼临床医学杂志(电子版).2006,2(3)：134
[14]Kadambi A, Carreira CM, Yun C, et al. Vascular endo—thelial growth factor(VEGF)—C differentially affects tumor vascular function and leukocyte:role of VEGF—receptor 2 and host VEGF_A[J]. cancer Res,2001, 61:2404-2408.
[15]胡亚敏,郑红兵.VEGF—C和ICAM-1在子宫腺肌病中的表达及意义[J].华中科技大学学报(医学版),2009,38(2)：218-219
[16]黄晓晖,康佳丽,王小霞,等.Bcl-2蛋白、Ki-67抗原、雌激素受体及孕激素受体在子宫腺肌病子宫内膜中的表达[J].中华生物医学工程杂志,2007,13(4)：198-199
[17]邓亚丽,胡春兰,李晓玲.Survivin在子宫腺肌病的表达及其与Bcl-2、Bax相关性的研究[J].医学研究杂志,2008年6月第,37(6)：17-18
[18]郑立红,岳丽玲,刘枫.Fas、FasL在子宫腺肌病中的表达及意义[J].中国优生与遗传杂志2005,13(12)：28-29
[19]蔡平平,张玉珍.活血化瘀方药对Poresky大鼠模型内皮细胞的影响[J].浙江中医药大学学报,2009,33(4)：484-485
[20]李跃文.舒血宁注射液与复方丹参注射液治疗冠心病心绞痛的临床观察[J].中华中西医杂志,2009,7(3)：68-69
[21]张霞,刘雨银,章正华,等.盐酸川芎嗪注射液对青霉素致痫大鼠血液流变学指标、血小板聚集率和血浆去甲肾上腺素水平的作用[J].微循环学杂志,2011,21(2)：16-18
[22]王芳,褚伟,祁友松.虎杖对实验性糖尿病大鼠血管内皮保护作用的观察[J].中医临床研究,2010,2(19)：21-23
[23]周卫,宿树兰,刘培等.蒲黄一五灵脂药对不同提取物活血化瘀效应的比较研究[J].南京中医药大学学报,2010,26(3)：211-213
[24]孙军,王贺玲,李岩.姜黄素对人肝癌细胞中血管内皮生长因子表达的影响[J].中华消化杂志,2006,26(12)：843-844
[25]张前,牛欣,闫妍,等.羟基红花黄色素A抑制新生血管形成的机制研究[J].北京中医药大学学报,2004,27(3)：25—29.
[26]徐晓玉,严鹏科,陈刚,等.川芎嗪对小鼠肺癌血管生长和VEGF表达的抑制[J].中国药理学通报,2004,20(2)：151—154.
[27]何秀娟,李萍,邱全瑛.外用中药有效成分对血管内皮细胞增殖作用的影响[J].中国病理生理杂志,2003,19(11)：1570.
[28]李琦,王炎,范忠泽,等.丹参酮Ⅱ A及其纳米粒诱导肝癌细胞凋亡及对p38MAPK、TGFB1信号蛋白表达的影响[J].肿瘤,2008,28(1)：8.
[29]刘特,黄文彬,赖东梅,等.姜黄素对人脑胶质瘤细胞凋亡作用及其对Bcl-2与Caspase 8诱导表达的影响[J].中国癌症杂志,2009,19(4)：247—251.
[30]Chen W, Lu Y, Gao M, et al. Anti—angiogenesis effect of essential oil from Curcuma zedoaria in vitro and in vivo[J]. J Ethnopharnmcol, 2011,133(1):220-226
[31]Tao J, Zhang P, Liu G, et al. Cytotoxicity of Chinese moth— erwort(YiMuCao)aqueous ethanol extract is non—apoptotic and estrogen receptor independent on human breast cancer cells[J]. Ethnopharmacol,2009,122(2):234-239.
[1]Liu D, Zhang Zh, Gladwell W, etal. Estrogen stimulates estrogen- related receptor gene expression through conserved hormone response elements [J]. Endocrinology,2003,144(11):4894-4904.
[2]Levy M, Mittal K, Chiriboga L, etc. Differential expression of selected gene products in uterine leiomyomata and adenomyosis[J]. Fertil Steril,2007,88(1):220-223
[3]高珍珍,宋磊,关铮.选择性雌激素受体13激动剂治疗小鼠子宫腺肌病的实验研究[J].中国妇产科临床杂志,2009,10(3)：210-211
[4]Claudia R, Vanesa A, Werner von W, et al. Expression of CO-stimulatory molecules, chemokine receptors and proin-flaramatory cytokines in dendritic cells from normal and chronically inflamed rat testis[J]. Mol Hum Reprod,2007,13(12):853-861.
[5]Wang J, Zhang HH, Duan H. Expression of ER a in endometrial-myometria interface of human adenomyosis[J]. Zhonghua Yi Xue Za Zhi. 2010,90(27):1914-1917.
[6]丁华峰,孔丽娜,孙青.子宫腺肌症中ER PR的表达[J].皖南医学院学报,2009,28(1)：25-26
[7]Hudelist G, Keckstein J, Czerwenka K, et al. Estrogen receptor beta and matrix metal]oproteinase are coexpressed in uterine endometrium and endometriotic lesions of patients with endometriosis[J]. Fertil Steril, 2005,84(2):1249-1256
[8]NieJC, Xishi LiuXS, Guo SW. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent[J]. Reprod Sci. 2010,17(11):995-1005.
[9]郑秋鸿.孕激素受体亚型在子宫腺肌病异位内膜中的表达及其意义[J].齐齐哈尔医学院学报,2007,1(28)：24-29
[10]陆晓媛.子宫腺肌病中孕激素受体亚型表达的研究[J].中国实用医药,2008,3(35)：45-46
[11]王敏,任霞,李欣,等.孕激素受体亚型在子宫腺肌病中的表达及意义[J]. 广东医学,2008,29(5)：709-710
[12]Choi YS, Cho S, Lim KJ, etal. Immunoreactivity of progesterone receptor isoform B, nuclear factor kappaB, and I kappaB alpha in adenomyosis[J]. Fertil Steril,2009,92(3):886-889
[13]廖谦和,胡树红,陈利琼,等.子宫腺肌症雌激素受体、孕激素受体与bcl-2的表达[J], Clin Exp Pathol,2006,22(6):663-664
[14]郭志荣,张琚,郎景和.子宫腺肌症患者在位子宫内膜雌激素效应相关因子的时空变化[J].中华妇产科杂志,2004,39(42)：246-247
[15]Heilier JF, Donnez 0, Kerckhove V, etal. Expression of aromatase (P450 aromatase/CYP19) in peritoneal and ovarian endometriotic tissues and deep endometriotic (adenomyotic) nodules of the rectovaginal septum[J]. Fertil Steril,2006,85(5):1516-1518.
[16]Hatok J, Zubor P, Galo S. Endometrial aromatase mRNA as a possible screening tool for advanced endometriosis and adenomyosis[J]. Gynecol Endocrinol,2010,6(17):354-357
[17]田永杰,周军,沈蓉.COX-2在子宫腺肌病患者子宫内膜和肌组织中的表达及意义[J].山东医药,2007,47(11)： 1-2
[18]Goteri G, Lucarini G, Montik N. Suppression of migratory/invasive ability and induction of apoptosis in adenomyosis-derived mesenchymal stem cells by cyclooxygenase-2 inhibitors[J]. Fertil Steril,2010, 94(6):1972-1979.
[19]曲晓媛,贾世磊,王言.芳香化酶P450与环氧化酶-2在子宫内膜异位症和子宫腺肌病中的表达及意义[J].中国现代医药杂志,2009,11(5)：27-28
[20]王言奎,徐冰,车艳辞.子宫内膜异位症和子宫腺肌病P450arom和COX-2mRNA的表达及意义[J].青岛大学医学院学报,2007,43(4)：326-328
[21]王毅峰,曲银娥,杨梅.COX-2基因多态性与子宫内膜异位症及子宫腺肌病关系的研究[J].山东医药,2007,47(15)：22-23
[2]魏绍斌,黄金燕,文怡.从湿瘀内结论治妇科慢性盆腔疼痛病症[J].四川中医,2012,30(4)：29—30
[3]魏绍斌,黄金燕,文怡.从湿瘀内结论治妇科慢性盆腔疼痛病症[J].四川中医,2012,30(4)：29—30
[4]魏绍斌,冯婷婷,王宇慧.从“源头治疗”子宫内膜异位症的中医新思路[J].新中医,2012,44(11)：14—16
[5]段峻.四物汤加味治疗子宫腺肌症51例[J].河北中医,1999,21(6)：363—364
[6]李所平.少腹逐瘀汤加味治疗子宫腺肌病50例[J].河北中医,2009,31(4)：592
[7]李学应,杨廉泽.散结汤治疗子宫肌瘤子宫腺肌症的临床研究[J].浙江中医药大学学报,2006,30(4)：365—367
[8]王清.“抑痛平”治疗子宫腺肌症痛经35例临床观察[J].中国康复理论与实践,2005,11(8)：651—652
[9]彭秀美.自拟验方治疗子宫腺肌症[J].中国医学杂志,2006,4(12)：683—684
[10]秦瑞英.散结镇痛胶囊治疗子宫腺肌症并不孕的临床观察[J].中国医药导报,2006,3(26)：95
[11]朱江艾.桂枝茯苓胶囊治疗子宫腺肌病56例[J].中华现代中西医杂志,2005,(13)：1218
[12]叶铤.子宫腺肌症的早期中药治疗.中国中医药信息杂志[J],2003,10(5)：47--48
[13]沈玉莲,金季玲.活血化淤法分期治疗子宫腺肌病27例临床观察[J].时珍国医国药,2006,17(10)：2037-2038
[14]李亚平.少腹逐瘀汤灌肠治疗子宫腺肌症32例[J].中医杂志,2003,44(1)：49
[15]侯钦銮,吕洪清,汪慧敏.药灸结合治疗子宫腺肌症的临床观察[J].浙江中医学院学报,2004,28(6)：42-43
[16]李琼,邓雪梅,赖慧红.健脾补肾祛瘀3法分期治疗子宫腺肌病20例临床观察[J].中医杂志,2004,45(7)：520—521
[17]刘秀峰,陈丽笙,何珍.大黄廑虫丸治疗子宫腺肌病30例观察[J].实用中医药杂志,2004,20(2)：64—65
[18]张秋晔,韩英俊,白晓玲.自拟谐宫汤活血化瘀药为主治疗子宫腺肌病的临床观察与优势[J].中国初级卫生保健,2008,11(22)：94—95
[19]邓雷厉.化瘀消瘸方合灌肠液治疗子宫腺肌病临床观察[J].中医药学刊,2005,23(3)：570-573
[20]田洪兰,麻增昌,刘传文.小剂量米非司酮配合中药治疗子宫腺肌病的临床观察[J].潍坊医学院学报,2005,27(6)：458-459
[21]曹丽蓉,李力.中西医结合治疗围绝经期子宫腺肌病60例[J].中国中西医结合杂志,2005,25(11)
[22]董小萍.中西医结合治疗子宫腺肌病30例[J].湖北中医杂志,2005,27(9)：34
[23]杨君,任艳芳,华芳芳.改良式手术联合散结镇痛胶囊治疗子宫腺肌症的临床研究[J].医学信息内外科版,2009年6,22(6)：501—503
[24]黄为宁,王劲琪,曹长健等.双侧子宫动脉栓塞联合中药治疗[J].时珍国医国药,2007,18(2)：475—476
[25]Wang J, Zhang HH, Duan H. Expression of ER a in endometrial—myometria interface of human adenomyosis[J]. Zhonghua Yi Xue Za Zhi.2010:90(27):1914-19177.
[26]陆晓媛.子宫腺肌病中孕激素受体亚型表达的研究[J].中国实用医药,2008,3(35)：45—46
[27]高珍珍,宋磊,关铮.选择性雌激素受体β激动剂治疗小鼠子宫腺肌病的实验研究[J].中国妇产科临床杂志2009,10(3)：210--211
[28]郭志荣,张琚,郎景和.子宫腺肌症患者在位子宫内膜雌激素效应相关因子的时空变化[J].中华妇产科杂志,2004,39(42)：246—247
[29]Jichan Nie, Xishi Liu, Guo SW. Promoter hypermethylation of progesterone receptor isoform B (PR—B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent[J]. Reprod Sci.2010,17(11):995-1005.
[30]Hatok J, Zubor P, Galo S. Endometrial aromatase mRNA as a possible screening tool for advanced endometriosis and adenomyosis[J]. Gynecol Endocrinol,2010,17:118-120
[31]黄晓晖,康佳丽,王小霞,等.Bcl-2蛋白、Ki-67抗原、雌激素受体及孕激素受体在 子宫腺肌病子宫内膜中的表达[J].中华生物医学工程杂志,2007,13(4)：198—199
[32]邓亚丽,胡春兰,李晓玲Survivin在子宫腺肌病的表达及其与Bcl-2、Bax相关性的研究[J].医学研究杂志,2008,37(6)：17-20
[33]郑立红,岳丽玲,刘枫Fas、FasL在子宫腺肌病中的表达及意义[J].中国优生与遗传杂志2005,13(12)：28—29
[34]Yang JH, Wu MY, Chen CD, Chen MJ, Yang YS, Altered apoptosis and proliferation in endometrial stromal cells of women with adenomyosis[J]. Ho HNHum Reprod.2007 Apr;22 (4):945-52.
[35]张爱群,孙富国,李金生,等cyclin E与P27蛋白在子宫腺肌病中的表达及临床意义[J].临床军医杂志,2007,35(1)：13—14
[36]张爱群,付红霞,孙富国,等Cyclin A与P2 1蛋白在子宫腺肌病中的表达及临床意义[J].河北医药,2007,29(11)：1163—1164
[37]张蓉,虞斌,许培箴,等.端粒酶在子宫腺肌病中的表达及其临床意义[J].中国临床医学,2007,14(6)：854—855
[38]刘俊宝,金海鸿,张爱臣.诱导细胞凋亡c—myc在子宫腺肌病中的表达及意义[J].中国实验诊断学,2008,12(4)：466—467
[39]Huang HY, Yu HT, Chan SH, Lee CL, Wang HS, Soong YK. Eutopic endometrial interleukin-18 system mRNA and protein expression at the level of endometrial—myometrial interface in adenomyosis patients[J]. Fertil Steril.2010 Jun;94(1):33-39.
[40]Wang F, Li H, Yang Z, Du X, Cui M, Wen Z Expression of interleukin-10 in patients with adenomyosis[J]. Fertil Steril.2009 May;91(5):1681-1685
[41]Ulukus M, Ulukus EC, Seval Y, Cinar O. Expression of interleukin-8 receptors in patients with adenomyosis [J]. Fertil Steril.2006 Mar; 85(3):714-720.
[42]Yang JH, Chen MJ, Wu MY, Chen YC, Yang YS, Ho HN.. Decreased suppression of interleukin-6 after treatment with medroxyprogesterone acetate and danazol in endometrial stromal cells of women with adenomyosis[J]. Fertil Steril.2006 Nov;86(5):1459-1465.
[43]曲晓媛,贾世磊,王言.芳香化酶P450与环氧化酶-2在子宫内膜异位症和子宫腺肌病 中的表达及意义[J].中国现代医药杂志,2009,11(5)：27--28
[44]王言奎,徐冰,车艳辞.子宫内膜异位症和子宫腺肌病P450arom和COX-2mRNA的表达及意义[J].青岛大学医学院学报,2007,43(4)：326—328
[45]王毅峰,曲银娥,杨梅.COX-2基因多态性与子宫内膜异位症及子宫腺肌病关系的研究[J].山东医药,2007,47(15)：55—57
[46]王杜平,王进京.子宫腺肌病患者在位与异位内膜热休克蛋白27的表达及意义[J].右江民族医学院学报,2007,29(3)：416—417
[47]Wang F, Wen Z, Li H, Yang Z, Zhao X, Yao X. Human leukocyte antigen—G is expressed by the eutopic and ectopic endometrium of adenomyosis[J]. Fertil Steril.2008 Nov; 90 (5):1599-1604.
[48]赵瑞,李艳,赵蔚.子宫腺肌病中异位子宫内膜血管发生的研究[J].医药论坛杂志,2007,28(21)：38-39
[49]吕晓霞,李楠.子宫腺肌病组织中PTTG、bFGF和VEGF的表达及意义[J].山东医药,2008,48(3)：97
[50]Kang S, Zhao J, Liu Q, Zhou R, Wang N, Li Y. Vascular endothelial growth factor gene polymorphisms are associated with the risk of developing adenomyosis[J]. Environ Mol Mutagen.2009 Jun; 50 (5):361-366.
[51]Liu Q, Li Y, Zhao J, etc. Association of single nucleotide polymorphisms in VEGF gene with the risk of endometriosis and adenomyosis[J]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi.2009 Apr;26(2):165-169.
[52]刘天凤,尹福波.子宫腺肌病组织中PTFG的表达与微血管密度和b-FGF的关系[J].现代妇产科进展,2007,16(4)：300
[53]马小梅,李娜萍,刘海防.中期因子在GnR H a治疗后子宫腺肌病患者在位和异位内膜组织中的表达[J].华中科技大学学报(医学版),2009,38(1)：64-65
[54]王水英,周彩云,付晓敏Ang-1和Ang-2在子宫内膜异位症及子宫腺肌病中的表达[J].中国妇产科临床杂志,2008,9(3)：77—78
[55]李梦熊,张怡,蔡净亭.促血管生成素-2在子宫内膜异位性疾病中的表达及其意义[J].中国医学工程,2007,15(1)：211-212
[56]胡亚敏,郑红兵VEGF-C和ICAM-1在子宫腺肌病中的表达及意义[J].华中科技大学 学报(医学版),2009,38(2)：218—219
[57]Zhang X, Lu B, Huang X, Xu H, Zhou C, etc. Innervation of endometrium and myometrium in women with painful adenomyosis and uterine fibroids [J]. Fertil Steril. 2010 Jul;94(2):730-737.
[58]Choi YS, Cho S, Lim KJ, Jeon YE, etc. Effects of LNG—IUS on nerve growth factor and its receptors expression in patients with adenomyosis [J]. Growth Factors.2010 Dec; 28 (6):452-460.
[59]李天真.蒲灵化瘀止痛方对子宫腺肌病模型小鼠异位和在位内膜血管生成相关因子不同影响的实验研究[D].成都中医药大学,2011.
[60]马俊彦,冯燕,许泓,等.小鼠子宫腺肌病模型的建立及ER的表达[J].中国保健营养(临床医学学刊),2009,18(4)：29—31
[61]廖英,李军兰,陈云飞.桂枝茯苓胶囊对子宫腺肌病小鼠病灶组织MMP-2、MMP-7的影响[J].中国中医药科技,2007,14(5)：328—330
[62]李雁,张绍芬,夏贤,等.口服他莫昔芬法建立ICR小鼠子宫腺肌病模型[J].中国实验动物学报,2009,17(5)：29—31
[63]张信美,邓琳,马俊彦,等.异体垂体移植诱发ICR小鼠子宫腺肌病动物模型的建立[J].现代妇产科进展,2007,16(4)：94--96
[64]李雁,张绍芬,夏贤,等.口服他莫昔芬法建立ICR小鼠子宫腺肌病模型[J].中国实验动物学报,2009,17(5)：：345—350
[65]尤昭玲,付灵梅,谭朝阳,等.三七有效成分对人子宫内膜细胞培养液TNF-α和IL—1β含量的影响[J].中国实验方剂学杂志,2005,11(2)：39—41
[66]孙蓬明,宋一一,高敏等.ERRa过度表达对子宫内膜癌Ishikawa细胞内分泌治疗的影响[J].中国妇产科临床杂志,2012,13(2)：126—127
[67]张宝玉,万杰PR、ER在食管癌组织中的表达及与预后的关系[J].山东医药,2012,52(43)：38—39
[68]李玉娟,谢静燕.雌激素受体基因多态性与子宫内膜异位症的相关性[J].安徽医药,2010,14(11)：1305—1307
[69]李靖,冯力民,刘晖.雌孕激素受体在子宫全层中的表达[J].武警医学,2011,22(12)：1049—1051
[70]华特波,孟宪瑛,张强,等.COX-2、MMP-9在甲状腺癌中的表达及临床意义[J].中国实验诊断学,2011,15(9)：1491—1493
[71]马静,何朝宏,任君凯,等COX-2、NF-κ BmR N A在肾透明细胞癌中的表达变化及意义[J].山东医药,2012,52(10)：75—77
[72]唐曼,吴强,吴正升,等.COX-2在食管鳞状细胞癌组织中的表达及相互关系[J].安徽医科大学学报；450-453
[73]邓莅霏,齐淑轶,刘学明,等COX-2、VEGF—C在头颈鳞癌中的表达及意义[J],赣南医学院学报,32(4)：515—517
[74]董毅,程艳香.COX-2和HIF—1α在宫颈鳞状细胞癌组织中的表达及意义[J].实用癌症杂志,2012,27(1)：36—37
[75]辛华,江清林,崔国利,等.COX-2和M MP—9在乳腺癌患者血清中检测的意义[J].中国病案,2012,13(2)：46—47
[76]李杰,陈剑秋,王新允,等.COX-2和MUC—1在乳腺癌中的表达及其临床意义[J].天津医科大学学报,2011,17(4)：479—481
[77]陈怡文,龚享文,刘春云.COX-2基因mRNA在非小细胞肺癌中的表达[J].临床肺科杂志2012,17(5)：935—936
[78]秦卫华,吕红凯.COX-2在肾癌中的表达及其临床意义[J].求医问药,2011,9(8)：11—13
[79]黄利娟,陈勃.COX-2在子宫内膜病变发生发展中的作用[J].广州医药,2012,43(3)：27—29
[80]孙丽,孙三元,卓士超,等HER-2、COX-2和VEGF在乳腺癌原发灶与复发转移灶之间的关系[J].临床肿瘤学杂志,2011,16(11)：984—987
[81]贾富鑫,刘江伟,张东.MMP—9和COX-2蛋白的表达对胰腺癌预后的影响[J].中华临床医师杂志(电子版),2011,5(7)：7191
[82]张帅,沈梁,谷维立,等VEGF、COX-2在甲状腺癌中的表达及临床意义[J].医学研究杂志,2012,41(2)：146—150
[83]马隽,陈晓明,钟艳平,等.骨肉瘤组织中COX-2、VEGF的表达及意义[J].山东医药,2011,51(10)：7—9
[84]奚豪,朱延波,蒋虹伟,等.食管癌COX-2和VEGF的表达及其与临床病理特征的关系[J]. 局解手术学杂志,2011,20(2)：157—159
[85]杨莉,刘廷健,鲍静娴.胃癌组织中COX-2和VEGF—CmRNA表达及意义[J].中国当代医药,2011,18(13)：10—12
[86]姚婷婷,章礼久,方海明.肠道细胞色素P450代谢酶研究进展[J].安徽医药,2012,16(6)：721—723
[87]徐永红,孙航,郭晖,等.肝再生增强因子、细胞色素P450与人肝癌细胞在体外耐药的关系[J].重庆医科大学学报,2011,6(3)：257—262
[88]高桂芹,林琬君,李宝森.芳香化酶细胞色素P450在子宫内膜异位症中的检测与临床意义[J].天津医药,38(12)：1050-1052
[89]黄秋穗,侯晓红.那曲唑对子宫内膜异位症芳香化酶P450、雌二醇及雌激素受体的影响[J].临床研究,2011,49(25)：54—56
[90]刘燕,康佳丽,王小霞VEGF、ENS、MVD在子宫腺肌病中的表达及意义[J].中国妇产科临床杂志,2009,10(5)：363—366
[91]刘春花,崔之础,张玉泉VEGF基因多态性与子宫内膜异位症的相关性研究[J].南通大学学报(医学版),2012,32(6)：513—515
[92]姚路明.基质金属蛋白酶MMP-2、MMP-9含量表达与大肠癌浸润转移相关性研究[J].吉林医学,2012,33(34)：7461—7462
[93]韩迎春,李剑,孙启玉,等.腹股沟直疝及斜疝患者皮肤组织MMP—2及T I MP—2的表达研究结论[J].现代中西医结合杂志.2012,21(22)：2403—2405
[94]李守勇,陈维霞,孙阳.类风湿性关节炎患者血清中s CR1和MMP-2、MMP-9水平的检测及其临床意义[J].中国实用医刊,2012,39(24)68—70
[95]夏正明.急性发作期支气管哮喘患者血清IL-18、MMP-9、COX-2水平的变化及意义[J].实用临床医学,2012,13(8)：22—24
[96]张弘炜,王太洪,卢有胜.MMP-2与HGF在胰腺癌组织中的表达及临床意义[J].中国肿瘤外科杂志,2012,4(6)：338—340
[97]李燕,郑芹林,唐利Int β1、MMP-2及PRL-3在子宫内膜异位症中的表达[J].山东医药,2012,52(41)：35—37
[98]胡倩,于丽,廖秦平.基质金属蛋白酶-2基因启动子的甲基化状态对子宫内膜癌侵袭力调控的分子机制[J].北京大学学报,44(6)：911—915
[99]Choi YS, Cho S, Lim KJ, etal. Immunoreactivity of progesterone receptor isoform B, nuclear factor kappaB, and I kappaB alpha in adenomyosis[J]. Fertil Steril, 2009,92(3):886-889
[100]Hudelist G, Keckstein J,Czerwenka K, et al. Estrogen receptor beta and matrix metalloproteinase are coexpressed in uterine endometrium and endometriotic lesions of patients with endometriosis[J].Fertil Steril,2005,84(2):1249-1256
[101]NieJC, Xishi LiuXS, Guo SW. Promoter hypermethylation of progesterone receptor isoform B (PR—B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent[J]. Reprod Sci.2010,17(11):995-1005.
[102]张拴成,肖红玲,王丽娜,等.消瘀通络散对乳腺增生大鼠乳头的动态变化、血清雌二醇、雌激素受体表达水平及病理组织形态的影响[J].浙江中医药大学学报,2012,36(4)：417—421
[103]骆殊,邵佳,沈洪,等.黄芪莪术配伍抑制MKN-45裸鼠人原位胃癌模型肿瘤生长、转移及COX-2表达的增效研究[J].时珍国医国药,2012,23(5)：1164—1165
[104]佘小翠,黄丽军,刘高峰,等.丹红注射液对大鼠肝微粒体5种CYP亚型酶活性的影响[J].医药导报,2012,31(3)：277—278
[105]段保宏,高完花,魏娜.四物合剂对大鼠肝微粒体代谢酶P450活性的影响[J].中国药物与临床,2011,11(5)：600—602
[106]应忠明,蔡永强,王恩智.实验性脑出血大鼠VEGF及MMP-9蛋白表达的影响及益气活血法的干预作用[J].中国高等医学教育,2012,12：131
[107]宗慧梅,王禹.活血化瘀中药对实验陛急性脑梗死大鼠脑组织VEGF、bFGFmRNA表达的影响[J].中国中医急症,2006,15(7)：766—767
[108]郭海,陈艳,尹刚,等.养肺活血方对肺纤维化大鼠肺组织血管新生的影响[J].南京中医药大学学报,2012,28(5)：467—468
[109]倪秀琴,魏仲南,林武,等.益肾通络方治疗慢性肾衰竭及与血清TGF-p、VEGF的相关研究[J].中国中西医结合肾病杂志,2012,13(12)：1099—1100
[110]孙垮,张苗,蒋春明.丹参酮ⅡA对腹膜透析患者基质金属蛋白酶及金属蛋白酶组织抑制剂-1的影响[J].医学研究生学报,2011,24(9)：913—914
[111]林薇,赵锦燕,郑良朴,等.血府逐瘀汤对大鼠血管平滑肌细胞MMP-2、TIMP-1表达 的影响[J].时珍国医国药,2011,22(11)：2667—2668
[112]姜元辉,段富津.益气养血化瘀汤对心肌缺血大鼠MMP-2和MMP-9蛋白表达的影响[J].中医药学报,2012,40(2)：47—49
[113]杨东霞,曲凡,马文光,等.活血化瘀法对子宫内膜异位症模型大鼠E2、P、VEGF的影响[J].成都中医药大学学报,2006,29(2)：28—30
[114]钟凌,袁立明.血府逐瘀汤对子宫肌瘤雌激素受体和BCL-2表达的影响[J].肿瘤药学,2012(1)：34—35
[115]唐润娟,程慧莲.消瘤丸对子宫内膜异位症大鼠异位病灶的影响[J].内蒙古中医药,2012,3：41-42
[116]杨正望,文炯,张增玲.补肾化瘀方对PCOS大鼠卵巢颗粒细胞CYP450表达的影响[J].湖南中医药大学学报,2011,31(1)：30—33
[117]杜永红,李沛霖,韩冰.补肾调冲方对去卵巢大鼠性激素水平及下丘脑雌激素受体a、雌激素受体β m RNA表达的影响[J].天津中医药,2011,28(3)：240—243
[118]姚菲,曹建雄,王若光.桂枝挥发油对PCOS大鼠模型卵巢VEGF、COX-2及MVD表达的影响[J].中医药导报,18(1)：15-17
[119]贺丰杰,李小宁,张文婷.凋膜止崩液宫腔靶向给药对ADUB模型大鼠子宫内膜组织中MMP-1、TIMP-1、ER及亚型表达的影响[J].时珍国医国药,2012,23(6)：1861—1863
[120]]丁青,李洁雅,徐杰,等.丹参注射液对中重度IUA患者宫内膜α V β 3、P DGF及TIMP-1的影响[J].湖南中医药大学学报,2012,32(10)：52—55
[121]A. Vivaequa, D. Bonofigli o, A. G. Recchia,et al.The G p rotein coupled receptor GPR30 mediates the proliferative eff ects induced by 17B-estradiol and hydroxytamoxifen in endometri M cancer cells [J].Mol Endocfinol,2006,20:631-646
[122]T. Smuc.M. Ribie—ueelj, J. inkovec, et al. Expression analy sis of the genes involved in estradiol and progesterone action in human ovarian endome-triosis [J].Gynecol Endocrinol,2007,23:105-111
[123]Bukulrn 0, Hardy D. B, Cart B. R, et al. Mendel son, Inflammato ry status influences aronmtase and steroid expression in endome triosis [J].Endocrinology,2008,149:1190-1204
[124]A. Vivaequa, D. Bonofigli o, A. G. Recchia, et al.The G p rotein coupled receptor GPR30 mediates the proliferative eff ects induced by 17B-estra-diol and hydroxytamoxifen in endometri M cancer cells [J]. Mol Endocfinol,2006,20:631-646
[125]端传友MMP-2、MMP-9及VEGF在结肠癌中的表达及其与肿瘤转移的相关性[J].中国医药导报,2012,9(21)：44—48
[1]赵瑞,李艳,赵蔚.子宫腺肌病中异位子宫内膜血管发生的研究[J].医药论坛杂志,2007,28(21)：38-39
[2]吕晓霞,李楠.子宫腺肌病组织中PTTG、bFGF和VEGF的表达及意义[J].山东医药,2008,48(3)：14-15
[3]Kang S, Zhao J, Liu Q, Zhou R, Wang N, Li Y. Vascular endothelial growth factor gene polymorphisms are associated with the risk of developing adenomyosis[J]. Environ Mol Mutagen,2009,50(5):361-366.
[4]. Liu Q, Li Y, Zhao J, etc. Association of single nucleotide polymorphisms in VEGF gene with the risk of endometriosis and adenomyosis[J]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi.2009 Apr; 26 (2):165-169.
[5]李梦熊,张怡,蔡净亭.促血管生成素-2在子宫内膜异位性疾病中的表达及其意义[J].中国医学工程,2007,15(1)：211-212
[6]陈华,马生秀.促红细胞生成素在子宫腺肌病组织的表达意义[J].青海医学院学报2009,30(1)：40
[7]Wang J, Zhang HH, Duan H. Expression of ER a in endometrial- myometria interface of human adenomyosis[J]. ZhonghuaYiXue ZaZhi.2010;90(27): 1914-19177.
[8]Ocher Klein K, Janfaza M, Wang J A, Chang R J. Estrogen bioactivity in fo-ti and other herbs used for their estrogen-like effects as determined by a recombinant cell bioassay[J]. J Clin Endocrinol Metab, 2003,88(9):4077-4079.
[9]曲晓媛,贾世磊,王言.芳香化酶P450与环氧化酶-2在子宫内膜异位症和子宫腺肌病中的表达及意义[J].中国现代医药杂志,2009,11(5)：27-28
[10]王言奎,徐冰,车艳辞.子宫内膜异位症和子宫腺肌病P450arom和COX-2mRNA的表达及意义[J].青岛大学医学院学报,2007,43(4)：326-328
[11]刘天凤,尹福波.子宫腺肌病组织中PTFG的表达与微血管密度和b-FGF的关系[J].现代妇产科进展,2007,16(4)：300
[12]刘素巧,董晓瑜,申莉瑛等.基质金属蛋白酶-2在子宫腺肌病子宫内膜-肌层界面的表达[J].河北医药,2009,31(2)：
[13]康佳丽,李莉,杜洪等.基质金属蛋白酶-7及其抑制因子-1在子宫腺肌 病中的表达及意义[J].中华妇幼临床医学杂志(电子版).2006,2(3)：134
[14]Kadambi A, Carreira CM, Yun C, et al. Vascular endo—thelial growth factor(VEGF)—C differentially affects tumor vascular function and leukocyte:role of VEGF—receptor 2 and host VEGF_A[J]. cancer Res,2001, 61:2404-2408.
[15]胡亚敏,郑红兵.VEGF—C和ICAM-1在子宫腺肌病中的表达及意义[J].华中科技大学学报(医学版),2009,38(2)：218-219
[16]黄晓晖,康佳丽,王小霞,等.Bcl-2蛋白、Ki-67抗原、雌激素受体及孕激素受体在子宫腺肌病子宫内膜中的表达[J].中华生物医学工程杂志,2007,13(4)：198-199
[17]邓亚丽,胡春兰,李晓玲.Survivin在子宫腺肌病的表达及其与Bcl-2、Bax相关性的研究[J].医学研究杂志,2008年6月第,37(6)：17-18
[18]郑立红,岳丽玲,刘枫.Fas、FasL在子宫腺肌病中的表达及意义[J].中国优生与遗传杂志2005,13(12)：28-29
[19]蔡平平,张玉珍.活血化瘀方药对Poresky大鼠模型内皮细胞的影响[J].浙江中医药大学学报,2009,33(4)：484-485
[20]李跃文.舒血宁注射液与复方丹参注射液治疗冠心病心绞痛的临床观察[J].中华中西医杂志,2009,7(3)：68-69
[21]张霞,刘雨银,章正华,等.盐酸川芎嗪注射液对青霉素致痫大鼠血液流变学指标、血小板聚集率和血浆去甲肾上腺素水平的作用[J].微循环学杂志,2011,21(2)：16-18
[22]王芳,褚伟,祁友松.虎杖对实验性糖尿病大鼠血管内皮保护作用的观察[J].中医临床研究,2010,2(19)：21-23
[23]周卫,宿树兰,刘培等.蒲黄一五灵脂药对不同提取物活血化瘀效应的比较研究[J].南京中医药大学学报,2010,26(3)：211-213
[24]孙军,王贺玲,李岩.姜黄素对人肝癌细胞中血管内皮生长因子表达的影响[J].中华消化杂志,2006,26(12)：843-844
[25]张前,牛欣,闫妍,等.羟基红花黄色素A抑制新生血管形成的机制研究[J].北京中医药大学学报,2004,27(3)：25—29.
[26]徐晓玉,严鹏科,陈刚,等.川芎嗪对小鼠肺癌血管生长和VEGF表达的抑制[J].中国药理学通报,2004,20(2)：151—154.
[27]何秀娟,李萍,邱全瑛.外用中药有效成分对血管内皮细胞增殖作用的影响[J].中国病理生理杂志,2003,19(11)：1570.
[28]李琦,王炎,范忠泽,等.丹参酮Ⅱ A及其纳米粒诱导肝癌细胞凋亡及对p38MAPK、TGFB1信号蛋白表达的影响[J].肿瘤,2008,28(1)：8.
[29]刘特,黄文彬,赖东梅,等.姜黄素对人脑胶质瘤细胞凋亡作用及其对Bcl-2与Caspase 8诱导表达的影响[J].中国癌症杂志,2009,19(4)：247—251.
[30]Chen W, Lu Y, Gao M, et al. Anti—angiogenesis effect of essential oil from Curcuma zedoaria in vitro and in vivo[J]. J Ethnopharnmcol, 2011,133(1):220-226
[31]Tao J, Zhang P, Liu G, et al. Cytotoxicity of Chinese moth— erwort(YiMuCao)aqueous ethanol extract is non—apoptotic and estrogen receptor independent on human breast cancer cells[J]. Ethnopharmacol,2009,122(2):234-239.
[1]Liu D, Zhang Zh, Gladwell W, etal. Estrogen stimulates estrogen- related receptor gene expression through conserved hormone response elements [J]. Endocrinology,2003,144(11):4894-4904.
[2]Levy M, Mittal K, Chiriboga L, etc. Differential expression of selected gene products in uterine leiomyomata and adenomyosis[J]. Fertil Steril,2007,88(1):220-223
[3]高珍珍,宋磊,关铮.选择性雌激素受体13激动剂治疗小鼠子宫腺肌病的实验研究[J].中国妇产科临床杂志,2009,10(3)：210-211
[4]Claudia R, Vanesa A, Werner von W, et al. Expression of CO-stimulatory molecules, chemokine receptors and proin-flaramatory cytokines in dendritic cells from normal and chronically inflamed rat testis[J]. Mol Hum Reprod,2007,13(12):853-861.
[5]Wang J, Zhang HH, Duan H. Expression of ER a in endometrial-myometria interface of human adenomyosis[J]. Zhonghua Yi Xue Za Zhi. 2010,90(27):1914-1917.
[6]丁华峰,孔丽娜,孙青.子宫腺肌症中ER PR的表达[J].皖南医学院学报,2009,28(1)：25-26
[7]Hudelist G, Keckstein J, Czerwenka K, et al. Estrogen receptor beta and matrix metal]oproteinase are coexpressed in uterine endometrium and endometriotic lesions of patients with endometriosis[J]. Fertil Steril, 2005,84(2):1249-1256
[8]NieJC, Xishi LiuXS, Guo SW. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent[J]. Reprod Sci. 2010,17(11):995-1005.
[9]郑秋鸿.孕激素受体亚型在子宫腺肌病异位内膜中的表达及其意义[J].齐齐哈尔医学院学报,2007,1(28)：24-29
[10]陆晓媛.子宫腺肌病中孕激素受体亚型表达的研究[J].中国实用医药,2008,3(35)：45-46
[11]王敏,任霞,李欣,等.孕激素受体亚型在子宫腺肌病中的表达及意义[J]. 广东医学,2008,29(5)：709-710
[12]Choi YS, Cho S, Lim KJ, etal. Immunoreactivity of progesterone receptor isoform B, nuclear factor kappaB, and I kappaB alpha in adenomyosis[J]. Fertil Steril,2009,92(3):886-889
[13]廖谦和,胡树红,陈利琼,等.子宫腺肌症雌激素受体、孕激素受体与bcl-2的表达[J], Clin Exp Pathol,2006,22(6):663-664
[14]郭志荣,张琚,郎景和.子宫腺肌症患者在位子宫内膜雌激素效应相关因子的时空变化[J].中华妇产科杂志,2004,39(42)：246-247
[15]Heilier JF, Donnez 0, Kerckhove V, etal. Expression of aromatase (P450 aromatase/CYP19) in peritoneal and ovarian endometriotic tissues and deep endometriotic (adenomyotic) nodules of the rectovaginal septum[J]. Fertil Steril,2006,85(5):1516-1518.
[16]Hatok J, Zubor P, Galo S. Endometrial aromatase mRNA as a possible screening tool for advanced endometriosis and adenomyosis[J]. Gynecol Endocrinol,2010,6(17):354-357
[17]田永杰,周军,沈蓉.COX-2在子宫腺肌病患者子宫内膜和肌组织中的表达及意义[J].山东医药,2007,47(11)： 1-2
[18]Goteri G, Lucarini G, Montik N. Suppression of migratory/invasive ability and induction of apoptosis in adenomyosis-derived mesenchymal stem cells by cyclooxygenase-2 inhibitors[J]. Fertil Steril,2010, 94(6):1972-1979.
[19]曲晓媛,贾世磊,王言.芳香化酶P450与环氧化酶-2在子宫内膜异位症和子宫腺肌病中的表达及意义[J].中国现代医药杂志,2009,11(5)：27-28
[20]王言奎,徐冰,车艳辞.子宫内膜异位症和子宫腺肌病P450arom和COX-2mRNA的表达及意义[J].青岛大学医学院学报,2007,43(4)：326-328
[21]王毅峰,曲银娥,杨梅.COX-2基因多态性与子宫内膜异位症及子宫腺肌病关系的研究[J].山东医药,2007,47(15)：22-23
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |